Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Vaccine Makers Capitalize On Provenge Fanfare At ASCO

Executive Summary

Heading into this year's American Society of Clinical Oncology meeting, beleaguered cancer immunotherapy developers finally have some cause for optimism about potential partnerships and, battle-hardened, they say they are hearty enough to wait for deals to roll in

You may also be interested in...



Takeda May Resurrect IDM’s Bone Cancer Drug Mifamurtide In U.S.

Fate of IDM’s dendritic cell-based Uvidem and other cancer vaccines remains unclear after $75 million purchase.

GlobeImmune Gets A Shot In The Arm Thanks To Celgene Cancer Collaboration

Hepatitis C vaccine success validated technology and paved way for the deal.

ASCO Abstracts Hold Some Surprises Including Data On AZ’s Vandetanib, Bristol’s Ipilimumab

Despite the lack of innovative drugs highlighted in ASCO's media briefing on its upcoming annual meeting, there is a range of oncology development updates that will be presented - including some surprises

Related Content

Topics

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel